First In Human Study

• First In Human Study is the initial phase of clinical research where a new drug or therapy is tested in humans.
• The primary objective is to assess the safety, tolerability, and preliminary pharmacokinetics of the investigational product.
• These studies involve a small group of healthy volunteers or patients with the target condition, under strict ethical and regulatory oversight.
• They are essential for determining a safe dose range and identifying potential side effects before proceeding to larger-scale efficacy trials.

What is a First In Human Study?

A First In Human Study (FIH), also known as a Phase 0 or Phase 1 clinical trial, is the earliest stage of clinical research where an experimental drug, vaccine, or medical device is administered to human subjects for the first time. This critical step follows extensive preclinical research, which includes laboratory and animal studies, demonstrating the potential safety and efficacy of the new intervention. The primary goal of these studies is not to prove effectiveness, but rather to establish a preliminary safety profile and understand how the human body processes the new substance.

These studies are meticulously designed and conducted under stringent ethical guidelines and regulatory oversight, such as those from the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). The process ensures the protection of participants, who are typically healthy volunteers or, in some cases, patients with advanced diseases for whom existing treatments have failed. The data collected from these studies are crucial for determining whether a new treatment is safe enough to proceed to further stages of clinical development. This initial phase of drug development is where first in human clinical trials explained the foundational understanding of a new compound’s interaction with the human body.

Purpose and Process of First In Human Studies

The overarching purpose of first in human studies is to gather essential preliminary information about a new investigational product that cannot be obtained from preclinical studies alone. These studies aim to answer fundamental questions regarding the drug’s safety, how it is absorbed, distributed, metabolized, and excreted by the body (pharmacokinetics), and its initial biological effects (pharmacodynamics). Identifying a safe dose range and potential side effects is paramount before the drug can be tested in larger populations for efficacy.

Key objectives typically include:

• Assessing the safety and tolerability of the investigational product in humans.
• Determining the pharmacokinetic profile, including absorption, distribution, metabolism, and excretion.
• Identifying the maximum tolerated dose (MTD) or the optimal biological dose.
• Gathering preliminary data on pharmacodynamic effects, if applicable.

How First In Human Studies Work

The execution of a First In Human Study involves a highly structured and carefully monitored process. After receiving regulatory approval, a small group of participants, typically 20-100 individuals, is enrolled. Participants are usually healthy volunteers, but for certain severe diseases like oncology, patients who have exhausted other treatment options may be included. The study design often involves dose escalation, where participants receive increasing doses of the investigational product in a controlled manner, with close monitoring for adverse events.

Throughout the study, participants undergo frequent medical evaluations, including physical examinations, blood tests, urine tests, and other specialized assessments to detect any changes in their health. Data on side effects, drug concentrations in the blood, and physiological responses are meticulously recorded and analyzed. This comprehensive data collection helps researchers understand the drug’s behavior in humans and guides decisions on whether to proceed to Phase 2 trials, where the drug’s efficacy is evaluated in a larger patient population. Ethical considerations, including informed consent and continuous monitoring by an Institutional Review Board (IRB) or Ethics Committee, are central to ensuring participant safety and well-being.